1
|
Turrisi AT, Glover DJ, Mason BA. Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for the treatment of limited small cell lung cancer: a preliminary report. Antibiot Chemother (1971) 2015; 41:109-14. [PMID: 2854429 DOI: 10.1159/000416190] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- A T Turrisi
- Department of Radiation Therapy, University of Pennsylvania, Philadelphia
| | | | | |
Collapse
|
2
|
Bogart J, Watson D, Seagren S, Blackstock AW, Wang X, Lenox R, Vokes E, Turrisi AT, Green MR. Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7556] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7556 Background: The optimal treatment for medically inoperable stage I NSCLC has not been defined. Methods: CALGB 39904 is a prospective phase I study assessing accelerated once-daily radiotherapy for early stage NSCLC. The primary objectives were to define the maximally accelerated course of conformal radiotherapy; and to describe the short-term and long-term toxicity of therapy. Entry was limited to patients with clinical stage T1N0 and T2N0 NSCLC (< 4 cm) with pulmonary dysfunction (FEV1 <40% predicted, DLCO 45mmHg, V02 max <15m1/kg/min, O2 requirement). The nominal total radiotherapy dose was held constant at 70 Gy, while the number of daily fractions in each successive cohort was reduced (table). Results: The study was activated on 12/15/2000, and closed on 7/29/2005. Forty patients were accrued with 8 on each cohort. One patient on cohort 5 declined protocol treatment leaving 39 eligible patients. Patients were generally female (53%), white (83%), and ECOG performance status = 1 (67%). The median age was 74 (range 48 to 87), and the majority of the patients (73%) had T1N0M0 disease. Treatment was well tolerated without grade 4+ toxicity. There was one hematologic toxicity (lymphopenia) in cohort 2, and one non-hematologic toxicity each in cohort 3 (dyspnea) and cohort 4 (pain).The major repsonse rate was 74% (31% complete response, 43 % partial response), and 26% of patients had stable disease. After a median follow-up of 38.1 months, 21 patients remain alive. The actuarial median survival of all eligible patients is 38.5 months (95% confidence interval= 19.45 to NE). Conclusion: Accelerated conformal radiotherapy was well tolerated in a high-risk population with clinical stage I NSCLC. Outcomes are comparable to prospective reports of alternative therapies, including stereotactic body radiosurgery and limited resection,with less apparent severe toxicity. Further investigation of this approach is warranted. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- J. Bogart
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - D. Watson
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - S. Seagren
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - A. W. Blackstock
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - X. Wang
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - R. Lenox
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - E. Vokes
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - A. T. Turrisi
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| | - M. R. Green
- SUNY Upstate Medcl Univ, Syracuse, NY; CALGB Statistical Center, Durham, NC; UCSD, San Diego, CA; Wake Forest School of Medicine, Winston- Salem, NC; University of Chicago, Chicago, IL; Wayne State University, Detroit, MI; Care Alliance Roper Hospital, Charleston, SC
| |
Collapse
|
3
|
Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR, Johnson DH, Green MR, Miller RC. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7014] [Citation(s) in RCA: 123] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. S. Albain
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - R. S. Swann
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - V. R. Rusch
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - A. T. Turrisi
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - F. A. Shepherd
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - C. J. Smith
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - D. R. Gandara
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - D. H. Johnson
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - M. R. Green
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| | - R. C. Miller
- Loyola Univ Chicago Med Ctr, Maywood, IL; Radiation Therapy Oncology Group, Philadelphia, PA; Memorial Sloan-Kettering Cancer Ctr, New York, NY; Wayne State University/Karmanos Cancer Ctr, Detroit, MI; Princess Margaret Hosp, Toronto, ON, Canada; Tom Baker Cancer Ctr, Calgary, AB, Canada; UC Davis Cancer Ctr, Sacramento, CA; Vanderbilt-Ingram Cancer Ctr, Nashville, TN; Medcl Univ of South Carolina, Charleston, SC; Mayo Clinic, Rochester, MN
| |
Collapse
|
4
|
Abstract
The improvements in the treatment of small cell lung cancer over the last 30 years have been realised by understanding that it is a systemic disease, but that areas of bulk and sanctuary require a complementary therapy. Despite successful strategies using combinations and thoracic radiotherapy, there remains uncertainty about what the best regimens are, their timing and their intensity. However, earlier concurrent therapy and rather brief intense chemotherapy and radiotherapy seem to produce the best results in moderately fit patients of all ages. How to select the fit patients and what to do about the less fit ones remains controversial and have economic consequences for governments and payers. Despite a meta-analysis demonstrating the success of prophylactic cranial irradiation (PCI), doubts linger about its safety, despite nothing more than anecdotal evidence from a previous era. The role of surgery continues to be explored, more in Europe than North America or Asia. Strategies for treatment of minimum residual disease seem a focus. New drugs, molecular targeted therapy, immunotherapy and other molecular therapies offer promise and theory, but there is little evidence about their place in the treatment protocols of today.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, POB 250318, Charleston, SC 29425, USA.
| | | |
Collapse
|
5
|
Thomas CR, Giroux DJ, Janaki LM, Turrisi AT, Crowley JJ, Taylor SA, McCracken JD, Shankir Giri PG, Gordon W, Livingston RB, Gandara DR. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer 2001; 33:213-9. [PMID: 11551416 DOI: 10.1016/s0169-5002(01)00181-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
PURPOSE To report the long-term follow-up of Southwest Oncology Group-8269, a phase II North American cooperative group trial of concurrent cisplatin, etoposide, vincristine (PEV), and thoracic radiotherapy (TRT) for limited small-cell lung cancer (L-SCLC). METHODS 114 eligible patients from 47 institutions enrolled between April, 1985 and March 1986. Patients had documented L-SCLC. Induction chemotherapy consisted of three cycles of PEV. TRT was administered at 1.8 Gy/fraction in 25 daily fractions to a total dose of 45 Gy, to begin concomitantly. Consolidative chemotherapy included two cycles of vincristine, methotrexate, etoposide, doxorubicin and cyclophosphamide. Prophylactic cranial irradiation (PCI) was concurrent with the 3rd cycle of chemotherapy. The PCI dose was 30 Gy in 15 fractions of 2 Gy/fraction. RESULTS As of May 2000, 5 of 114 remain alive and progression-free with a minimum follow-up interval of 13.2 years, as of May 2000. The median follow-up interval is 14.2 years. Thirty eight patients died of causes other than SCLC and five patients are still alive and progression-free. Of the remaining 71 patients dying of SCLC, local failure (LF) occurred in 24% (17 patients), distant metastasis (DM) occurred in 35% (25 patients), simultaneous LF and DM occurred in 25% (18 patients), and was indeterminate in 16% (11 patients). Thus, LF was a component of failure in 49%. Twenty patients had the CNS as the initial site of failure. Eleven patients (10%) developed fatal second primary cancers, including two with acute myelogenous leukemia, two with squamous cell lung cancer, one each with breast, pancreas, prostate, renal cell, and myelodysplasia. One patient developed both a melanoma and non-Hodgkin's lymphoma. CONCLUSION There are long-term survivors with concomitant TRT and PEV. LF and DM are common. Pattern of failure suggests needs to improve local and systemic control.
Collapse
Affiliation(s)
- C R Thomas
- Department of Radiation Oncology, San Antonio Cancer Institute, University of Texas Health Science Center, San Antonio, TX, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA.
| |
Collapse
|
7
|
Hayman JA, Martel MK, Ten Haken RK, Normolle DP, Todd RF, Littles JF, Sullivan MA, Possert PW, Turrisi AT, Lichter AS. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001; 19:127-36. [PMID: 11134205 DOI: 10.1200/jco.2001.19.1.127] [Citation(s) in RCA: 270] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
PURPOSE High-dose radiation may improve outcomes in non-small-cell lung cancer (NSCLC). By using three-dimensional conformal radiation therapy and limiting the target volume, we hypothesized that the dose could be safely escalated. MATERIALS AND METHODS A standard phase I design was used. Five bins were created based on the volume of normal lung irradiated, and dose levels within bins were chosen based on the estimated risk of radiation pneumonitis. Starting doses ranged from 63 to 84 Gy given in 2.1-Gy fractions. Target volumes included the primary tumor and any nodes >or= 1 cm on computed tomography. Clinically uninvolved nodal regions were not included purposely. More recently, selected patients received neoadjuvant cisplatin and vinorelbine. RESULTS At the time of this writing, 104 patients had been enrolled. Twenty-four had stage I, four had stage II, 43 had stage IIIA, 26 had stage IIIB, and seven had locally recurrent disease. Twenty-five received chemotherapy, and 63 were assessable for escalation. All bins were escalated at least twice. Although grade 2 radiation pneumonitis occurred in five patients, grade 3 radiation pneumonitis occurred in only two. The maximum-tolerated dose was only established for the largest bin, at 65.1 Gy. Dose levels for the four remaining bins were 102.9, 102.9, 84 and 75.6 Gy. The majority of patients failed distantly, though a significant proportion also failed in the target volume. There were no isolated failures in clinically uninvolved nodal regions. CONCLUSION Dose escalation in NSCLC has been accomplished safely in most patients using three-dimensional conformal radiation therapy, limiting target volumes, and segregating patients by the volume of normal lung irradiated.
Collapse
Affiliation(s)
- J A Hayman
- Department of Radiation Oncology, Division of Hematology/Oncology, University of Michigan Health System, Ann Arbor, MI, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, Aisner SC, Livingston RB, Blum R, Johnson DH. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000. [PMID: 11064352 DOI: 10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m(2), Day 1 and etoposide 120 mg/m(2), Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61% vs. 84%; P < 0.01) and fatal toxicity (1% vs. 10%; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%; P = 0.11), event free survival rate (5 year, 19% vs. 16%; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches.
Collapse
Affiliation(s)
- A R Yuen
- Stanford University Medical Center, Stanford, California, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, Aisner SC, Livingston RB, Blum R, Johnson DH. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000. [PMID: 11064352 DOI: 10.1002/1097-0142(20001101)89: 9<1953: : aid-cncr11>3.3.co; 2-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m(2), Day 1 and etoposide 120 mg/m(2), Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61% vs. 84%; P < 0.01) and fatal toxicity (1% vs. 10%; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%; P = 0.11), event free survival rate (5 year, 19% vs. 16%; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches.
Collapse
Affiliation(s)
- A R Yuen
- Stanford University Medical Center, Stanford, California, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, Aisner SC, Livingston RB, Blum R, Johnson DH. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89:1953-60. [PMID: 11064352 DOI: 10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m(2), Day 1 and etoposide 120 mg/m(2), Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61% vs. 84%; P < 0.01) and fatal toxicity (1% vs. 10%; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%; P = 0.11), event free survival rate (5 year, 19% vs. 16%; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches.
Collapse
Affiliation(s)
- A R Yuen
- Stanford University Medical Center, Stanford, California, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Williams TE, Thomas CR, Turrisi AT. Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol 2000; 10:315-23. [PMID: 11040332 DOI: 10.1053/srao.2000.9613] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The treatment of non-small cell lung cancer has continued to evolve with the advent of improved staging technologies, chemotherapeutic agents, and methods of radiation delivery. Treatment of clinically uninvolved, regional lymph nodes historically has been delivered in the attempt to cover unseen disease, reduce regional failure, and improve survival. None of these suppositions has been tested nor are they supported by data. With enhanced staging using modalities like positron emission tomography and esophageal ultrasonography, treatment portals can be designed to encompass known disease with greater accuracy and confidence. Data for early-stage non-small cell lung cancer is now increasing and strongly suggest that eliminating elective nodal irradiation does not result in a high incidence of nodal relapse and does not compromise survival. Three-dimensional conformal radiotherapy incorporates better targeting and beam directions to effect smaller treatment volumes that include only clinically evident disease. It provides treatment techniques that maximize tumor dose and minimize normal tissue toxicity. Using smaller fields that do not incorporate elective nodal regions may allow higher doses, and these may help improve local control and survival in a disease where current results are unacceptable.
Collapse
Affiliation(s)
- T E Williams
- Department of Radiation Oncology, the Medical University of South Carolina, Charleston, SC 29425, USA
| | | | | |
Collapse
|
12
|
Sherman CA, Rocha Lima CM, Turrisi AT. Limited small-cell lung cancer: a potentially curable disease. Oncology (Williston Park) 2000; 14:1395-403; discussion 1403-4, 1409. [PMID: 11098505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Patients with limited-stage small-cell carcinoma of the lung are treated with combined-modality therapy with the intent to cure. Standard therapy consists of platinum-based combination chemotherapy, thoracic irradiation, and for responders, prophylactic cranial irradiation. Despite this aggressive approach, too few patients achieve 5-year survival. In the past several years, new chemotherapeutic agents, including the taxanes and the topoisomerase I inhibitors, have demonstrated substantial activity against small-cell carcinoma. These agents are now being incorporated into clinical trials for patients with limited-stage disease. The best combination of these agents with platinum-based regimens is yet to be determined, and data supporting increased survival are awaited. Other studies are exploring thoracic radiation issues. Questions remain regarding optimal timing, dose, volume, and fractionation schemes. The most effective combination of thoracic irradiation and the newer chemotherapy agents also remains to be determined. The current approach to limited-stage small-cell carcinoma is reviewed, ongoing trials are described, and future directions are explored.
Collapse
Affiliation(s)
- C A Sherman
- Division of Hematology/Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, USA
| | | | | |
Collapse
|
13
|
Nuyttens JJ, Rust PF, Thomas CR, Turrisi AT. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer 2000. [PMID: 10738207 DOI: 10.1002/(sici)1097-0142(20000401)88] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND Desmoid tumors (aggressive fibromatoses) are benign neoplasms with high rates of recurrence after surgery. Radiotherapy is sometimes reported to prevent recurrences, but not in all studies. In order to evaluate the effect of radiation, comparative analysis was performed. METHODS The authors conducted a MEDLINE search and collected all articles in the English language on the treatment of "desmoid tumor" or "aggressive fibromatosis" from the years 1983-1998. They categorized treatment into three groups: surgery alone (S), surgery with radiotherapy (S + RT), or radiotherapy alone (RT). The S and S + RT groups were each subdivided according to whether margins were free (-), positive (+), or unknown. Each subgroup was divided into cases with primary, recurrent, or unknown tumor. RESULTS The local control rates after treatment for cases in the S group with (-) margins, (+) margins, and overall were 72%, 41%, and 61%, respectively. For the S + RT group the local control results were 94%, 75%, and 75%, respectively, significantly different when compared with the results for the S group. For the RT group, the local control was 78%, significantly superior to that of the S group (61%). Cases with primary and recurrent tumors had significantly superior local control rates with S + RT or RT versus S. Radiotherapy complications noted were fibrosis, paresthesias, edema, and fracture. CONCLUSIONS RT or S + RT results in significantly better local control than S. Even after dividing the groups into cases with free and positive margins and cases with primary and recurrent tumors, the best local control is achieved with RT or S + RT.
Collapse
Affiliation(s)
- J J Nuyttens
- Department of Radiation Oncology, Medical University of South Carolina, Charleston 29425, USA
| | | | | | | |
Collapse
|
14
|
Milito SJ, Turrisi AT. Radiotherapy in prostate cancer: improvements in an effective treatment and future prospects of further gains. J S C Med Assoc 2000; 96:65-8. [PMID: 10710902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Radiation therapy has useful applications in the management of all stages of prostate cancer. Modern advances have improved the efficacy of radiotherapy, and have lowered the toxicity. Radiotherapy offers patients with early stage, clinically localized disease a non-invasive curative option that has low toxicity. Patients with metastatic prostate cancer can be palliated with judicious use of radiotherapy.
Collapse
Affiliation(s)
- S J Milito
- Department of Radiation Oncology, MUSC, Charleston, SC 29425, USA
| | | |
Collapse
|
15
|
Martel MK, Ten Haken RK, Hazuka MB, Kessler ML, Strawderman M, Turrisi AT, Lawrence TS, Fraass BA, Lichter AS. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999; 24:31-7. [PMID: 10403692 DOI: 10.1016/s0169-5002(99)00019-7] [Citation(s) in RCA: 277] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Tumor control probability (TCP) model calculations may be used in a relative manner to evaluate and optimize three-dimensional (3-D) treatment plans. Using a mathematical model which makes a number of simplistic assumptions, TCPs can be estimated from a 3-D dose distribution of the tumor given the dose required for a 50% probability of tumor control (D50) and the normalized slope (gamma) of the sigmoid-shaped dose-response curve at D50. The purpose of this work was to derive D50 and gamma from our clinical experience using 3-D treatment planning to treat non-small cell lung cancer (NSCLC) patients. Our results suggest that for NSCLC patients, the dose to achieve significant probability of tumor control may be large (on the order of 84 Gy) for longer (> 30 months) local progression-free survival.
Collapse
Affiliation(s)
- M K Martel
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-71. [PMID: 9920950 DOI: 10.1056/nejm199901283400403] [Citation(s) in RCA: 969] [Impact Index Per Article: 38.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND For small-cell lung cancer confined to one hemithorax (limited small-cell lung cancer), thoracic radiotherapy improves survival, but the best ways of integrating chemotherapy and thoracic radiotherapy remain unsettled. Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy. METHODS We studied 417 patients with limited small-cell lung cancer. All the patients received four 21-day cycles of cisplatin plus etoposide. We randomly assigned these patients to receive a total of 45 Gy of concurrent thoracic radiotherapy, given either twice daily over a three-week period or once daily over a period of five weeks. RESULTS Twice-daily treatment beginning with the first cycle of chemotherapy significantly improved survival as compared with concurrent once-daily radiotherapy (P=0.04 by the log-rank test). After a median follow-up of almost 8 years, the median survival was 19 months for the once-daily group and 23 months for the twice-daily group. The survival rates for patients receiving once-daily radiotherapy were 41 percent at two years and 16 percent at five years. For patients receiving twice-daily radiotherapy, the survival rates were 47 percent at two years and 26 percent at five years. Grade 3 esophagitis was significantly more frequent with twice-daily thoracic radiotherapy, occurring in 27 percent of patients, as compared with 11 percent in the once-daily group (P<0.001). CONCLUSIONS Four cycles of cisplatin plus etoposide and a course of radiotherapy (45 Gy, given either once or twice daily) beginning with cycle 1 of the chemotherapy resulted in overall two- and five-year survival rates of 44 percent and 23 percent, a considerable improvement in survival rates over previous results in patients with limited small-cell lung cancer.
Collapse
Affiliation(s)
- A T Turrisi
- Medical University of South Carolina, Charleston 29425, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Vokes EE, Gregor A, Turrisi AT. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 1998; 25:66-9. [PMID: 9728588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Patients with stage III non-small cell lung cancer (NSCLC) frequently progress either within the irradiated field or systemically, due to uncontrolled microscopic dissemination present before the time of initial diagnosis. The use of combined modality therapy has led to improved survival rates in recent years. In particular, the use of cisplatin and vinblastine as induction chemotherapy is supported by two large randomized clinical trials. Nevertheless, the large majority of patients still die of progressive disease, thus providing a rationale for the integration of new active agents into the overall treatment plan of these patients. Gemcitabine has demonstrated significant single-agent activity in NSCLC. In addition, preclinical and early clinical data indicate that it is a powerful radiation enhancer. Clinical trials investigating this drug with concurrent radiation therapy in NSCLC are reviewed.
Collapse
Affiliation(s)
- E E Vokes
- Department of Medicine, University of Chicago Medical Center, and the Cancer Research Center, IL 60637-1470, USA
| | | | | |
Collapse
|
18
|
Milito SJ, Thomas CR, Turrisi AT. Advancements in radiotherapy and improved outcomes in prostate cancer. J S C Med Assoc 1998; 94:257-62. [PMID: 9648407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- S J Milito
- Department of Radiation Oncology, Medical University of South Carolina, Charleston 29425, USA
| | | | | |
Collapse
|
19
|
|
20
|
Turrisi AT. Integrating thoracic radiotherapy in the treatment of limited small-cell lung cancer. Oncology (Williston Park) 1998; 12:15-8. [PMID: 9516606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Although the need to combine thoracic radiotherapy with systemic chemotherapy in the curative treatment of limited small-cell lung cancer is now widely acknowledged, there is substantial disagreement on how best to do this. This paper reviews radiotherapeutic factors but also highlights the important interactions that occur with some classes of chemotherapeutics. Studies examining variables like dose and volume are clearly in order. Concurrent therapy given early has been adopted throughout most of the world, except Europe. The reasons for this are explored. Multiple studies are now showing excellent results with fewer total cycles of chemotherapy. Integration of newer drugs is another challenge for clinical investigators at the close of this century.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, Medical University of South Carolina, Charleston, USA
| |
Collapse
|
21
|
Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys 1998; 40:155-61. [PMID: 9422572 DOI: 10.1016/s0360-3016(97)00584-1] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE The influence of treatment parameters, such as (a) fraction size and (b) average and maximum dose (as derived from three-dimensional (3D) distributions), on the incidence of pericarditis was analyzed. To understand and predict the dose and volume effect on the pericardium, a normal tissue-complication probability model was tested with these complication data. METHODS AND MATERIALS Patients (n = 57) entered in 3 consecutive University of Michigan protocols of combined modality for treatment of localized esophageal carcinoma, and having 3D treatment planning for radiation therapy were the subject of this study. Univariate and multivariate analyses were performed to determine the significance of the effect of fraction size and dose parameters on the development of any grade of pericarditis. Dose distributions were corrected for the biological effect of fraction size using the linear-quadratic method. Normal tissue complication probability (NTCP) was calculated with the Lyman model. RESULTS Nonmalignant pericardial effusions occurred in 5 of the 57 patients; all effusions were in patients who received treatment with 3.5 Gy daily fractions. On multivariate analysis, no dose factor except fraction size predicted pericarditis, until the dose distributions were corrected for the effect of fraction size ("bio"-dose). Then, both "bio-average" and "bio-maximum" dose were significant predictive factors (p = 0.014). NTCPs for the patients with pericarditis range from 62% to 99% for the calculations with the "bio"-dose distributions vs. 0.5% to 27% for the uncorrected distributions. DISCUSSION A normal tissue complication probability (NTCP) model predicts a trend towards a high incidence of radiation pericarditis for patients who have high complication probabilities. It is important to correct the dose distribution for the effects of fractionation, particularly when the fraction size deviates greatly from standard (2.0 Gy) fractionation.
Collapse
Affiliation(s)
- M K Martel
- University of Michigan Medical Center, Department of Radiation Oncology, Ann Arbor 48109, USA
| | | | | | | | | |
Collapse
|
22
|
Thomas CR, Milito S, Turrisi AT. Hypofractionation, not rapid-fractionation. J Clin Oncol 1997; 15:3291-3. [PMID: 9336369 DOI: 10.1200/jco.1997.15.10.3291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
23
|
Turrisi AT. Concurrent chemoradiotherapy for limited small-cell lung cancer. Oncology (Williston Park) 1997; 11:31-7. [PMID: 9330406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
It is now established that the treatment of choice for limited small-cell lung cancer (SCLC) in the United States, Canada, and Japan is thoracic radiotherapy (TRT) combined with etoposide (VePesid), either alone or in conjunction with other agents, especially a platinum agent. The specific factors related to the use of TRT in the treatment of limited SCLC are: (1) dose (total and daily), (2) volume to be irradiated, (3) fractionation, (4) timing of radiation relative to chemotherapy (concurrent, at the same time; alternating, using both within weeks; or sequential, all of one followed by all of the other without any overlap), (5) whether radiation should be given earlier or later in the treatment course, and (6) whether to use a split course (rest intervals during a course of radiotherapy) or a continuous course of radiation. This paper discusses each of these factors.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, Medical University of South Carolina, Charleston, USA
| |
Collapse
|
24
|
Abstract
BACKGROUND AND PURPOSE To determine the effect of tumor volume and dose factors derived from 3-D treatment planning dose distributions on survival outcome for non-small cell lung cancer patients. MATERIALS AND METHODS Seventy-six consecutive patients diagnosed with medically inoperable or locally advanced, unresectable non-small cell lung cancer planned with 3-D treatment planning between 1986 and 1992 were the subject of this retrospective study. Patient characteristics and dosimetric parameters were analyzed for influence on overall survival and local progression-free survival (LPFS) using univariate and multivariate analysis. RESULTS Nodal stage and stage were the most significant factors for overall survival and LPFS duration on both univariate and multivariate analysis. We found a wide range of primary tumor volume sizes for each stage. Patients with tumor volumes <200 cm3 had longer survival (P = 0.047). In an analysis stratifying patients into four groups by tumor volume (<200 cm3 versus >200 cm3) and nodes (negative versus positive), patients in the group with no nodal disease and <200 cm3 tumor volumes survived longer than patients in any other group (P = 0.046). No dose factors were statistically significant for longer survival. Longer LPFS was seen for (a) isocenter dose >70 Gy (P = 0.055) for the overall group of patients, (b) within a subgroup with no nodal disease and >73 Gy (P = 0.054), and (c) within a subgroup with no nodal disease and tumor volume <200 cm3 receiving >73 Gy (P = 0.086). CONCLUSIONS Several findings from the volume and dosimetric analysis in this study are noteworthy. Stage was found to be a poor predictor of primary tumor volume size. Also, tumor volume size (<200 cm3) in conjunction with nodal status (negative nodes) had an impact on survival though there was a mix of stage (I, IIIa, IIIb) in this group of patients. Finally, dose appears to influence local control (LPFS) for the overall group of patients and when tumor volumes are <200 cm3. Our data indicate that outcome following radiation may be better predicted by a staging system that takes into account tumor volume and nodal spread rather than a system that is largely based on anatomic location of disease. Dose prescription for lung cancer treatment might better be written based on tumor volume size.
Collapse
Affiliation(s)
- M K Martel
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109, USA
| | | | | | | | | | | |
Collapse
|
25
|
Robertson JM, Ten Haken RK, Hazuka MB, Turrisi AT, Martel MK, Pu AT, Littles JF, Martinez FJ, Francis IR, Quint LE, Lichter AS. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37:1079-85. [PMID: 9169816 DOI: 10.1016/s0360-3016(96)00593-7] [Citation(s) in RCA: 149] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
PURPOSE Improved local control of non-small cell lung cancer (NSCLC) may be possible with an increased dose of radiation. Three-dimensional radiation treatment planning (3D RTP) was used to design a radiation therapy (RT) dose escalation trial, where the dose was determined by (a) the effective volume of normal lung irradiated, and (b) the estimated risk of a complication. Preliminary results of this trial were reviewed. METHODS AND MATERIALS A graph of the iso-normal tissue complication probability (NTCP) levels associated with a dose and effective volume (V(eff)) was derived, using normal tissue parameters derived from the literature. This led to a dose escalation schema, where patients were sorted into 1 of 5 treatment bins, determined by the V(eff) of the best possible treatment plan. The starting doses ranged from 63 to 84 Gy. Each treatment bin was then escalated separately, as in Phase I dose escalation fashion, with Grade > or = 3 radiation pneumonitis defined as dose limiting. To allow for dose escalation, we required patient follow-up to be > or = 6 months for at least three patients. 3D treatment planning was used to irradiate only the radiographically abnormal areas, with 2.1 Gy (corrected for lung inhomogeneity)/day. Clinically uninvolved lymph nodes were not treated prophylactically. RESULTS A total of 48 NSCLC patients have been treated (Stage I/II: 18 patients; Stage III: 28 patients; mediastinal recurrence postsurgery: 2 patients). No radiation pneumonitis has been observed in the 30 patients currently evaluable beyond the 6-month time point. All treatment bins have been escalated at least once. Current doses in the five treatment bins are 69.3, 69.3, 75.6, 84, and 92.4 Gy. None of the 15 evaluable patients in any bin with > or = 30% NTCP experienced clinical radiation pneumonitis, implying that the actual risk is < 20% (beta error rate 5%). Despite the observation of the clinically negative lymph nodes at high risk, there has been no failure in the untreated mediastinum as the sole site of first failure. Three of 10 patients receiving > or = 84 Gy have had biopsy proven residual or locally recurrent disease. CONCLUSION Successful dose escalation in a volume-dependent organ can be performed using this technique. By incorporating the effective volume of irradiated tissue, some patients have been treated to a total dose of radiation over 50% higher than traditional doses. The literature-derived parameters appear to overestimate pneumonitis risk with higher volumes. There has been no obvious negative effect due to exclusion of elective lymph node radiation. When completed, this trial will have determined the maximum tolerable dose of RT as a single agent for NSCLC and the appropriate dose for Phase II investigation.
Collapse
Affiliation(s)
- J M Robertson
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Williams TE, Turrisi AT. Role of radiotherapy in the treatment of small cell lung carcinoma. Chest Surg Clin N Am 1997; 7:135-49. [PMID: 9001761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Radiotherapy is an important component in the treatment of limited stage small cell carcinoma of the lung. It improves both local control and survival. This article reviews the scientific and clinical data that have led to combined therapy being considered the current standard for care of limited stage disease. Questions of radiation dose, treatment volume, fractionation, and integration with chemotherapy are discussed. New avenues of investigation to reduce toxicity and optimize treatment efficacy are also discussed.
Collapse
Affiliation(s)
- T E Williams
- Department of Radiation Oncology, Medical University of South Carolina, Charleston, USA
| | | |
Collapse
|
27
|
|
28
|
Naida JD, Eisbruch A, Schoeppel SL, Sandler HM, Turrisi AT, Lichter AS. Analysis of localization errors in the definition of the mantle field using a beam's eye view treatment-planning system. Int J Radiat Oncol Biol Phys 1996; 35:377-82. [PMID: 8635947 DOI: 10.1016/0360-3016(96)00085-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
PURPOSE Reports of the treatment of Hodgkin's disease (HD) with radiotherapy using the mantle field technique have demonstrated that coverage of disease by the field blocks significantly compromises outcome. It is our hypothesis that the availability of computerized tomography images reduces the incidence of localization error, and that the use of beam's eye view treatment planning techniques may further improve localization. The purpose of this report is to assess the possible contribution of a three-dimensional treatment-planning system to tumor localization and mantle block drawing in patients with HD. MATERIALS AND METHODS We evaluated the localization error rate of four experienced radiation oncologists as they drew the lung blocks for the mantle field. The analysis included 16 patients treated with mantle fields in our department between 1989 and 1991. In each case our computerized three-dimensional treatment planning system was used to generate a beam's eye view display of tumor volumes. Simulation radiographs for all 16 patients were overlaid with acetate film, and lung blocks were drawn by clinicians using only the simulation radiographs for reference. The process was repeated with the thoracic CT scans available for reference. The mantle block contours for each trial were then superimposed upon the beam's eye view plots of tumor volumes. The beam's eye view plot was our benchmark for the evaluation of errors of tumor localization. Localization errors were defined as touching or overlap of the shielding blocks onto tumors. RESULTS There was a high degree (p < 0.0003) of consistency in scoring across all pairing of clinicians and the results from all four were polled for the analysis. The overall error rate using the simulation radiographs alone was 18%. The rate was significantly lower (13%) when the CT images were available (p = 0.038). The axillary region had the highest localization error rate (41.7% with CT available and 27.1% with CT available) and the superior mediastinum had the lowest error rate (10.7% without CT, 8.5% with CT). Compared with a system such as beam's eye view, which could reduce the localization error rate to zero, the error rate with CT scans available is still significant [95% confidence interval (CI = 10-17.1%)]. Localization errors were more likely with increasing tumor size when CT scans were not available (p = 0.029). A similar trend was not seen when CT scans were available (p = 0.2). In a multivariate analysis, the use of CT scans predicted for reduced localization error rate (p = 0.03). Tumors in the axilla and inferior mediastinum had a greater relative risk than those in the superior mediastinum (p = 0.0001) CONCLUSION The availability of CT imaging offers an advantage in the outlining of the mantle field in the treatment of Hodgkin's disease. When the error rate is evaluated using a beam's eye view treatment planning system, a significant proportion of tumors may be overlapped by the outlined mantle blocks even when CT images are available for reference. The use of beam's eye view treatment planning in mantle field definition, especially for tumors in the axillary region, may reduce the incidence of geographic misses.
Collapse
Affiliation(s)
- J D Naida
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109, USA
| | | | | | | | | | | |
Collapse
|
29
|
Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880-92. [PMID: 7636530 DOI: 10.1200/jco.1995.13.8.1880] [Citation(s) in RCA: 695] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE To assess the feasibility of concurrent chemotherapy and irradiation (chemoRT) followed by surgery in locally advanced non-small-cell lung cancer (NSCLC) in a cooperative group setting, and to estimate response, resection rates, relapse patterns, and survival for stage subsets IIIA(N2) versus IIIB. PATIENTS AND METHODS Biopsy proof of either positive N2 nodes (IIIAN2) or of N3 nodes or T4 primary lesions (IIIB) was required. Induction was two cycles of cisplatin and etoposide plus concurrent chest RT to 45 Gy. Resection was attempted if response or stable disease occurred. A chemoRT boost was given if either unresectable disease or positive margins or nodes was found. RESULTS The median follow-up time for 126 eligible patients [75 stage IIIA(N2) and 51 IIIB] was 2.4 years. The objective response rate to induction was 59%, and 29% were stable. Resectability was 85% for the IIIA(N2) group eligible for surgery and 80% for the IIIB group. Reversible grade 4 toxicity occurred in 13% of patients. There were 13 treatment-related deaths (10%) and 19 others (15%) died of causes not related to toxicity or tumor. Of 65 relapses, 11% were only locoregional and 61% were only distant. There were 26 brain relapses, of which 19 were the sole site or cause of death. There was no survival difference (P = .81) between stage IIIA(N2) versus stage IIIB (median survivals, 13 and 17 months; 2-year survival rates, 37% and 39%; 3-year survival rates, 27% and 24%). The strongest predictor of long-term survival after thoracotomy was absence of tumor in the mediastinal nodes at surgery (median survivals, 30 v 10 months; 3-year survival rates, 44% v 18%; P = .0005). CONCLUSION This trimodality approach was feasible in this Southwest Oncology Group (SWOG) study, with an encouraging 26% 3-year survival rate. An Intergroup study is currently being conducted to determine whether surgery adds more to the risk or to the benefit of chemoRT.
Collapse
Affiliation(s)
- K S Albain
- Loyola University Medical Center, Maywood, IL, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, University of Michigan Medical Center, USA
| |
Collapse
|
31
|
Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205. [PMID: 7707407 DOI: 10.1093/jnci/87.3.198] [Citation(s) in RCA: 503] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Regionally advanced, surgically unresectable non-small-cell lung cancer represents a disease with an extremely poor prognosis. External-beam irradiation to the primary tumor and regional lymphatics is generally accepted as standard therapy. The use of more aggressive radiation regimens and the addition of cytotoxic chemotherapy to radiotherapy have yielded conflicting results. Recently, however, results from clinical trials using innovative irradiation delivery techniques or chemotherapy before irradiation have indicated that patients treated with protocols that incorporate these modifications may have higher survival rates than patients receiving standard radiation therapy. PURPOSE On the basis of these results, the Radiation Therapy Oncology Group (RTOG)-Eastern Cooperative Oncology Group (ECOG) elected to conduct a phase III trial comparing the following regimens: 1) standard radiation therapy, 2) induction chemotherapy followed by standard radiation therapy, and 3) twice-daily radiation therapy. METHODS Patients with surgically unresectable stage II, IIIA, or IIIB non-small-cell lung cancer were potential candidates. Staging was nonsurgical. Patients were required to have a Karnofsky performance status of 70 or more and weight loss less than 5% for 3 months prior to entry into the trial, to be older than 18 years of age, and to have no metastatic disease. Of the 490 patients registered in the trial, 452 were eligible. The disease in 95% of the patients was stage IIIA or IIIB. More than two thirds of the patients had a Karnofsky performance status of more than 80. Patients were randomly assigned to receive either 60 Gy of radiation therapy delivered at 2 Gy per fraction, 5 days a week, over a 6-week period (standard radiation therapy); induction chemotherapy consisting of cisplatin (100 mg/m2) on days 1 and 29 and 5 mg/m2 vinblastine per week for 5 consecutive weeks beginning on day 1 with cisplatin, followed by standard radiation therapy starting on day 50; or 69.6 Gy delivered at 1.2 Gy per fraction twice daily (hyperfractionated radiation therapy). RESULTS Toxicity was acceptable, with four treatment-related deaths. Three patients subsequently died of chronic pulmonary complications. Compliance with protocol treatment was acceptable. One-year survival (%) and median survival (months) were as follows: standard radiation therapy--46%, 11.4 months; chemotherapy plus radiotherapy--60%, 13.8 months; and hyperfractionated radiation therapy--51%, 12.3 months. The chemotherapy plus radiotherapy arm was statistically superior to the other two treatment arms (logrank P = .03). CONCLUSIONS In "good-risk" patients with surgically unresectable non-small-cell lung cancer, induction chemotherapy followed by irradiation was superior to hyperfractionated radiation therapy or standard radiation therapy alone, yielding a statistically significant short-term survival advantage.
Collapse
Affiliation(s)
- W T Sause
- Radiation Therapy Department, LDS Hospital, UT 84143, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
BACKGROUND Patients with metastatic or unresectable carcinoma of the esophagus have poor survival, but often require palliation of dysphagia. METHODS Twenty-seven patients with unresectable carcinoma of the esophagus were treated with carboplatin, 5-fluorouracil, and split-course accelerated radiation therapy. Seventy-four percent of patients had adenocarcinoma, and 26% had squamous cell carcinoma. RESULTS The regimen was well tolerated; 25% of the patients had disease improvement after completing therapy, although the majority of these patients had all of their disease within the radiation field. Ninety-three percent (13/14) of the patients who experienced disease progression during therapy progressed in areas treated with chemotherapy alone. Median survival was 6 months. Fifty-nine percent of the 17 patients who presented with dysphagia achieved durable relief of that symptom. CONCLUSIONS Carboplatin and 5-fluorouracil have low activity in patients with metastatic esophageal cancer. However, in combination with radiation therapy, this regimen is tolerable when the primary goal is palliation of dysphagia near the end of life. Future studies should focus on identifying more active regimens with response and survival as endpoints.
Collapse
Affiliation(s)
- S G Urba
- University of Michigan Medical Center, Ann Arbor, Michigan 48109
| | | |
Collapse
|
33
|
Abstract
The presentation, radiographic findings and course of 17 children with MRI-documented intrinsic midbrain lesions are reviewed. The anatomic centers of all the lesions were tectal, peritectal, or tegmental. Lesions centered at the pineal gland were excluded. Signs of increased intracranial pressure from hydrocephalus requiring shunt placement were present in 14 patients. Histopathological diagnosis was confirmed in three tumors; these were low grade astrocytomas and all received focal irradiation, as did one unbiopsied tumor. The remaining 13 patients with no histopathological diagnosis received no therapy other than shunt placement in 11. All but one of the lesions have remained clinically and radiographically stable, with a 4-year progression-free and total survival of 94 and 100%, respectively. We conclude that mass lesions originating in the upper midbrain are a subset of intrinsic brainstem tumors with a relatively benign course, usually presenting with hydrocephalus after infancy. They may remain stable for considerable periods and may require no further therapy after treatment of hydrocephalus. Surgical biopsy and/or resection can usually be reserved for progressive or atypical lesions which may also require further adjuvant therapy.
Collapse
Affiliation(s)
- P L Robertson
- Department of Pediatrics, University of Michigan Medical Center, Ann Arbor 48109-0570, USA
| | | | | | | | | | | |
Collapse
|
34
|
Turrisi AT. Platinum combined with radiation therapy in small cell lung cancer: focusing like a laser beam on crucial issues. Semin Oncol 1994; 21:36-42. [PMID: 8052872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The addition of radiotherapy to combination chemotherapy has been shown to improve survival for patients with limited small cell lung cancer (SCLC). Although SCLC is very sensitive to radiotherapy, the impact of radiation may be confounded by interaction among various radiotherapy factors or by the chemotherapeutic agents used in combination. The potential effects of such radiation factors as dose, volume, fractionation, sequence with chemotherapy, and timing (early v late), as well as choice of chemotherapy, therefore must be carefully considered when designing or comparing clinical trials of combined modality therapy for SCLC. The combination of thoracic radiotherapy plus platinum-based chemotherapy currently represents the cornerstone of such combination treatment for SCLC. Many questions remain, however, and it is hoped that new trials will be designed to focus more precisely on unsettled issues.
Collapse
Affiliation(s)
- A T Turrisi
- University of Michigan Medical Center, Department of Radiation Oncology, Ann Arbor 48109
| |
Collapse
|
35
|
Roa WH, Hazuka MB, Sandler HM, Martel MK, Thornton AF, Turrisi AT, Urba S, Wolf GT, Lichter AS. Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinuses. Int J Radiat Oncol Biol Phys 1994; 28:857-65. [PMID: 8138438 DOI: 10.1016/0360-3016(94)90105-8] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
PURPOSE This study reports our clinical experience supporting the normal tissue-sparing capability of 3-dimensional (3-D) treatment planning when applied to advanced neoplasms of the paranasal sinuses. METHODS AND MATERIALS Between 1986 and 1992, computed tomography (CT)-based 3-D radiotherapy was used to treat 39 patients with advanced stage malignant tumors of the paranasal sinuses as all or part of initial treatment. Fifteen unresectable patients were treated with primary radiotherapy to a median prescribed total dose of 68.4 Gy. Twenty-four patients were treated with postoperative adjuvant radiotherapy for close margins (< 5 mm), microscopic or gross residual disease. The median prescribed total doses were 55.8 Gy, 59.4 Gy and 67.8 Gy, respectively. Globe-sparing fields were used in the primary treatment plans of 37 patients (95%). The median follow-up is 4.5 years (range, 19-86 months). RESULTS For the unresectable patients who were treated with radiotherapy alone, the local control rate at 3 years is 32%. The actuarial overall survivals at 3 and 4 years are 32%. For the patients who received postoperative adjuvant radiotherapy, none of the five patients irradiated for close surgical margins recurred locally. Three of the 14 with microscopic residual (21%) recurred locally at 26, 63, and 74 months from the start of irradiation. Four of the five with gross residual (80%) recurred locally with a median time to recurrence of 2 years. The local control rates at 3 and 5 years for the adjuvant group are 75% and 65%, respectively. The actuarial overall survival at 3 and 5 years are 65% and 60%, respectively. None of the first sites of local disease progression were judged to have occurred outside the high-dose region. There was one case of mild osteoradionecrosis successfully treated with conservative treatment, one case of limited optic neuropathy and one case of possible radiation-induced cataract. There was no blindness related to irradiation. CONCLUSION This study indicates that computed tomography-based 3-D radiotherapy can preserve critical structures unaffected by tumor invasion and achieve the generally expected local control rates when it is used as all or part of initial treatment for extensive malignant tumors of the paranasal sinus. The presence of gross disease was a major adverse prognostic factor in this study. Additional therapeutic maneuvers are essential to improve the local control and survival rate in patients with advanced paranasal sinus carcinomas.
Collapse
Affiliation(s)
- W H Roa
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
The factors of dose, volume, fractionation, and timing with chemotherapy undoubtedly influence outcomes in terms of treatment of limited small cell lung cancer with thoracic radiotherapy. The type and timing with chemotherapy may be very important. For integration of chemotherapy with radiation therapy, the measure of iso-effects, for tumor and acute tissue and late effects, may be hard to come by. This paper relates a variety of different total doses, according to the relative scales provided by nominal standard dose (NSD, NRET) and the biologic effective dose (Gy-10 and Gy-3), which employs the alphabeta linear quadratic model. A variety of different fraction schemes have been used clinically. These allow us to compare intensifying of the dose versus standard treatment versus relative prolongation of the dose. When defined as measure of 2-year survivals, there is not a tremendous difference in observed outcomes. However, there may be differences that are discerned later when the endpoint local control is examined. This paper reviews the current pilot studies using platinum-etoposide chemotherapy, at a variety of different dose-intensive regimens of thoracic radio-therapy and their relative effects. To prove benefit, randomized trials are needed.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109
| |
Collapse
|
37
|
Martel MK, Ten Haken RK, Hazuka MB, Turrisi AT, Fraass BA, Lichter AS. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994; 28:575-81. [PMID: 8113100 DOI: 10.1016/0360-3016(94)90181-3] [Citation(s) in RCA: 227] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
PURPOSE Tolerance of normal lung to inhomogeneous irradiation of partial volumes is not well understood. This retrospective study analyzes three-dimensional (3-D) dose distributions and dose-volume histograms for 63 patients who have had normal lung irradiated in two types of treatment situations. METHODS AND MATERIALS 3-D treatment plans were examined for 21 patients with Hodgkin's disease and 42 patients with nonsmall-cell lung cancer. All patients were treated with conventional fractionation, with a dose of 67 Gy (corrected) or higher for the lung cancer patients. A normal tissue complication probability description and a dose-volume histogram reduction scheme were used to assess the data. Mean dose to lung was also calculated. RESULTS Five Hodgkin's disease patients and nine lung cancer patients developed pneumonitis. Data were analyzed for each individual independent lung and for the total lung tissue (lung as a paired organ). Comparisons of averages of mean lung dose and normal tissue complication probabilities show a difference between patients with and without complications. Averages of calculated normal tissue complication probabilities for groups of patients show that empirical model parameters correlate with actual complication rates for the Hodgkin's patients, but not as well for the individual lungs of the lung cancer patients treated to larger volumes of normal lung and high doses. CONCLUSION This retrospective study of the 3-D dose distributions for normal lung for two types of treatment situations for patients with irradiated normal lung gives useful data for the characterization of the dose-volume relationship and the development of pneumonitis. These data can be used to help set up a dose escalation protocol for the treatment of nonsmall-cell lung cancer.
Collapse
Affiliation(s)
- M K Martel
- Department of Radiation Oncology, University of Michigan, Ann Arbor 48109
| | | | | | | | | | | |
Collapse
|
38
|
Turrisi AT. Cisplatin-etoposide based chemoradiation treatment for limited small cell lung cancer: the current situation. Anticancer Res 1994; 14:289-93. [PMID: 8166469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Although the role of thoracic radiotherapy in limited small cell lung cancer has been established by two meta-analyses, optimization of radiotherapy with chemotherapy requires a full understanding of the chemotherapeutics used and the factors involved in administration of thoracic radiotherapy. The Cisplatin-Etoposide (PE) combination has replaced the cyclophosphamide or doxorubicin as the combination of choice, but it isn't clear whether the addition of the other agents add to benefit or toxicity. New agents continue to be sought to improve systemic failure. This paper focuses on the radiotherapy variables: dose, volume, fractionation, temporal sequencing, and variety of methods of combining the modalities are discussed. Results of a variety of pilot studies using thoracic radiotherapy and the PE combination are discussed. A randomized trial of accelerated radiotherapy versus standard fractionation has been completed within the past year, but results are not yet available. Further trials are warranted to improve integration of modalities in order to increase survival and reduce local and systemic failure without increasing untoward effects.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109
| |
Collapse
|
39
|
Wiatrak BJ, Koopmann CF, Turrisi AT. Radiation therapy as an alternative to surgery in the management of intracranial juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol 1993; 28:51-61. [PMID: 8300314 DOI: 10.1016/0165-5876(93)90146-t] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Juvenile nasopharyngeal angiofibroma is a benign, vascular tumor which typically presents in adolescent males. Although surgical resection is usually recommended for the management of this tumor, external beam radiation therapy has also been advocated in the literature. We report three cases of large juvenile nasopharyngeal angiofibromas with extensive intracranial extension primarily managed with external beam radiation therapy. Although there was not complete resolution of the tumors, there was significant alleviation of symptomatology with no serious side effects from the radiation therapy. Based on these cases, we feel that external beam radiation therapy in the management of extensive juvenile nasopharyngeal angiofibromas with intracranial extension is warranted in certain select cases.
Collapse
Affiliation(s)
- B J Wiatrak
- Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical Center Ann, Arbor
| | | | | |
Collapse
|
40
|
Ten Haken RK, Martel MK, Kessler ML, Hazuka MB, Lawrence TS, Robertson JM, Turrisi AT, Lichter AS. Use of Veff and iso-NTCP in the implementation of dose escalation protocols. Int J Radiat Oncol Biol Phys 1993; 27:689-95. [PMID: 8226166 DOI: 10.1016/0360-3016(93)90398-f] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
PURPOSE This report investigates the use of a normal tissue complication probability (NTCP) model, 3-D dose distributions, and a dose volume histogram reduction scheme in the design and implementation of dose escalation protocols for irradiation of sites that are primarily limited by the dose to a normal tissue which exhibits a strong volume effect (e.g., lung, liver). METHODS AND MATERIALS Plots containing iso-NTCP contours are generated as a function of dose and partial volume using a parameterization of a NTCP description. Single step dose volume histograms are generated from 3-D dose distributions using the effective-volume (Veff) reduction scheme. In this scheme, the value of Veff for each dose volume histogram is independent of dose units (Gy, %). Thus, relative dose distributions (%) may be used to segregate patients by Veff into bins containing different ranges of Veff values before the assignment of prescription doses (Gy). The doses for each bin of Veff values can then be independently escalated between estimated complication levels (iso-NTCP contours). RESULTS AND CONCLUSION Given that for the site under study, an investigator believes that the NTCP parameterization and the Veff methodology at least describe the general trend of clinical expectations, the concepts discussed allow the use of patient specific 3-D dose/volume information in the design and implementation of dose escalation studies. The result is a scheme with which useful prospective tolerance data may be systematically obtained for testing the different NTCP parameterizations and models.
Collapse
Affiliation(s)
- R K Ten Haken
- Department of Radiation Oncology, University of Michigan, Ann Arbor 48109-0010
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Hazuka MB, Turrisi AT, Lutz ST, Martel MK, Ten Haken RK, Strawderman M, Borema PL, Lichter AS. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis. Int J Radiat Oncol Biol Phys 1993; 27:273-84. [PMID: 8407401 DOI: 10.1016/0360-3016(93)90238-q] [Citation(s) in RCA: 78] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
PURPOSE To review the University of Michigan clinical experience in nonsmall cell lung cancer using high-dose thoracic irradiation (> or = 60 Gy) so that a starting dose for our prospective dose-escalation study could be determined. METHODS AND MATERIALS Eighty-eight consecutive patients diagnosed with medically inoperable or locally advanced, unresectable nonsmall cell lung cancer were identified who were treated with thoracic irradiation alone to a minimum total dose of 60 Gy (uncorrected for lung density). All patients except four (95%) underwent computed tomography scanning for treatment planning that included beam's eye view display for tumor and critical structure localization. All patients were treated with standard fractionation in a continuous course to uncorrected total doses ranging from 60 to 74 Gy (median, 67.6 Gy). RESULTS The median follow-up exceeds 24 months for all surviving patients (range, 12 to 78 months). The median survival time was 15 months, and the 2- and 3-year overall actuarial survival rates were 37% and 15%, respectively. Survival was significantly different between stage of disease (p = .004) and N-stage (p = .002) by univariate analysis. In a multivariate analysis, stage becomes the only characteristic significantly associated with outcome. The median time to local progression for 86 evaluable patients was 29 months. Stage (p = .0003), T-stage (p = .0095) and N-stage (p = .027) were significantly different with respect to local progression-free survival by univariate analysis. However, only stage was prognostic for local progression-free survival by multivariate analysis. There was no difference between large volume treatment (inclusion of the contralateral hilar and supraclavicular lymph nodes) and small volume treatment (exclusion of these elective nodal sites) with respect to local progression-free survival (p = .507) or survival (p = .520). With regard to dose, there was no significant difference between patients who received > 67.6 Gy and patients who received < or = 67.6 Gy with respect to local progression-free survival (p = .094) or survival (p = .142). Within the Stage III subgroup, local progression-free survival (p = .018) and survival (p = .061) were longer favoring the high-dose group of patients. Despite these doses, disease progression within the irradiated field was the predominant first site of treatment failure. CONCLUSION This retrospective study has shown that it is feasible to deliver uncorrected tumor doses as high as 70 Gy using standard fractionation in NSCLC with acceptable morbidity. Local control remains a significant problem. These data indicate justification for a starting dose in a prospective radiation dose-escalation study.
Collapse
Affiliation(s)
- M B Hazuka
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Johnson DH, Turrisi AT, Chang AY, Blum R, Bonomi P, Ettinger D, Wagner H. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:879-84. [PMID: 8387577 DOI: 10.1200/jco.1993.11.5.879] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
PURPOSE This pilot study was undertaken to determine the efficacy and feasibility of alternating cisplatin and etoposide with multiple daily fractions of thoracic radiotherapy (TRT) in patients with limited-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS Thirty-four SCLC patients received four courses of cisplatin (30 mg/m2/d x 3) plus etoposide (120 mg/m2/d x 3) (PE) every 3 weeks. TRT was administered twice daily (1.5 Gy per fraction) for 5 consecutive days in the week after cycles 1, 2, and 3 of chemotherapy (total TRT dose, 45 Gy). Patients who achieved a complete response (CR) received one course of late-intensification (LI) treatment consisting of cyclophosphamide (4 g/m2) and etoposide (900 mg/m2). Prophylactic cranial irradiation (PCI) was optional. RESULTS Nineteen of 32 assessable patients achieved a CR (59%) and 12 had a partial response (38%), for an overall response rate of 97% (95% confidence interval [CI], 84% to 99%). Median survival was 18 months, while 2-year progression-free survival was 47%. Leukopenia < or = 1,000/microL occurred in 12% of induction treatment cycles. Severe esophagitis was uncommon. Pulmonary fibrosis that was asymptomatic or minimally symptomatic was observed in eight patients (25%). There was one episode of adult respiratory distress syndrome (ARDS) during LI chemotherapy. Life-threatening neutropenia (< or = 500/microL) developed in all patients who underwent LI chemotherapy, with a median duration of 10 days (range, 8 to 19). Two patients died of sepsis during LI chemotherapy. CONCLUSION Alternating PE and TRT as performed in this trial is an effective brief induction regimen for limited-stage SCLC. However, this particular regimen did not appear to be substantially different in terms of efficacy or toxicity compared with regimens using concurrent chemotherapy and standard-fraction TRT. LI chemotherapy was associated with unacceptable toxicity and did not appear to have a favorable impact on survival.
Collapse
|
43
|
Abstract
Although systemic failure continues to plague patients receiving combined-modality treatment for limited small-cell lung cancer (SCLC), improvements in chemotherapy, including use of cisplatin/etoposide-based regimens, and radiotherapy have produced increases in median, 2-year, and 5-year survival over the last decade. Employing more conservative volumes of radiotherapy in more aggressive ways, today about 50% of SCLC patients will survive 2 years and 30%, 5 years. Moreover, integrating radiotherapy with chemotherapy early in the course of treatment can potentially eliminate resistant clones. The various factors in radiotherapy, including dose, volume, fractionation, and timing, therefore deserve scrutiny in the reporting and design of clinical trials.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor
| |
Collapse
|
44
|
Hazuka MB, Turrisi AT. The evolving role of radiation therapy in the treatment of locally advanced lung cancer. Semin Oncol 1993; 20:173-84. [PMID: 8386856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
RT has been used routinely in the treatment of NSCLC and SCLC for the past several decades. Although largely considered a palliative treatment by most oncologists, there is increasing evidence that RT, when combined with cisplatin-based chemotherapy or given by altered fractionation, may improve the survival in NSCLC. Three large randomized trials have now shown that RT plus a cisplatin-based combination or cisplatin alone prolongs patient survival. Studies of hyperfractionation and accelerated hyperfractionation have also shown promise and are being tested in randomized trials worldwide. The results from these trials must be assessed against ongoing radiation dose escalation studies using new treatment planning technologies, albeit still in their infancy. These trials are discussed in this report. Systemic therapy is the cornerstone of treatment for SCLC. Although the value of RT was hotly debated during the 1970s and 1980s, it is now well established that RT improves survival when combined with chemotherapy in limited stage patients. Despite this advancement, other issues (such as timing or sequencing of modalities, radiation dose, fractionation, and treatment volume), remain unsettled. Randomized trials designed to address these important issues are in progress.
Collapse
Affiliation(s)
- M B Hazuka
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor
| | | |
Collapse
|
45
|
Turrisi AT. Innovations in multimodality therapy for lung cancer. Combined modality management of limited small-cell lung cancer. Chest 1993; 103:56S-59S. [PMID: 8380135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Recent approaches to the treatment of limited small-cell lung cancer have combined local radiotherapy and systemic chemotherapy in an attempt to improve local control and inhibit distant metastases. Local control is a key indicator of the efficacy of radiotherapy administration in combined-modality regimens. However, even in combined-modality trials using high total radiotherapy doses, local failure rates have ranged from 30 to 50 percent. The components of radiotherapy administration--including dose, volume, fractionation, integration with chemotherapy (concurrent, alternating, or sequential), and timing (early or late administration)--are also important considerations. Hyperfractionation, or the administration of small fractions of radiation more than once daily (usually twice), and accelerated hyperfactionation, or the administration of three fourths of the standard radiation dose two to three times daily, have emerged as important concepts in radiotherapy. Although the optimal chemotherapy regimen for combined-modality treatment has not yet been established, use of cisplatin and etoposide combinations, which do not promote pulmonary, cardiac, or esophageal toxicity, have been particularly appropriate in patients with small-cell lung cancer.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor
| |
Collapse
|
46
|
Turrisi AT. Innovations in multimodality therapy for lung cancer. Combined modality management of limited small-cell lung cancer. Chest 1993. [DOI: 10.1378/chest.103.1.56s] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
47
|
Turrisi AT. The sound and fury about postoperative therapy for lung cancer. Mayo Clin Proc 1992; 67:1197-200. [PMID: 1469932 DOI: 10.1016/s0025-6196(12)61151-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
48
|
Turrisi AT. The integration of platinum and radiotherapy in the treatment of lung cancer. Semin Oncol 1991; 18:81-7. [PMID: 2003231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Combined-modality therapy in lung cancer is a common practice throughout the world. The use of radiochemotherapy appears to be firmly established in the treatment of small cell lung cancer, but the role of prophylactic cranial irradiation remains undecided. Many recommend its use in the treatment of non-small cell lung cancer as well, but no facts exist to support this position. Because of poor long-term outcome and high frequency of systemic relapse, integration of chemotherapy for the treatment of non-small cell lung cancer is becoming more prevalent. This article discusses methods of integration, the problems of combined- modality toxicity, recent trials, and reports of multimodal therapy in lung cancer. The advantages of certain regimens of chemotherapy and new methods of radiotherapy are also discussed.
Collapse
Affiliation(s)
- A T Turrisi
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor 48109
| |
Collapse
|
49
|
Abstract
In limited small cell lung cancer (LSCLC), the high local failure rate of chemotherapy by itself (60-100%) and with the addition of external beam radiotherapy (approximately 30%) has led to investigation of methods to improve local control. To that end, we integrated Platinum 60 mg/m2, d. 1, 22 and Etoposide 120 mg/m2, d. 4, 6, & 8; 25, 27 & 29 with concurrent twice-daily 150 cGy (total dose: 4500 cGy). Of 32 consecutively referred patients, 4 with variant histology, 31 were evaluable for toxicity, response, and survival. Two of 4 variant histology patients responded, and 27 of 27 pure small cell responded, p = 0.005. CT scans were inaccurate at forecasting survival. Of 17/32 patients considered "positive," 59% of these were survivors; of those considered "negative," 47% were survivors, p = N.S. Radiation portals were volumetrically conservative; the supraclavicular fossa was included infrequently and the contralateral hilum not at all. Local failure occurred in only 1/27 patients (4%). All four variant patients failed locally, p = 0.001. With a median follow-up of 43 months, the actuarial disease-free survival remains nearly 50%. Variant histology is more predictive of local control than the physical factors of dose or volume.
Collapse
Affiliation(s)
- A T Turrisi
- Radiation Oncology, University of Michigan, Ann Arbor 48109
| | | |
Collapse
|
50
|
Sandler HM, Curran WJ, Turrisi AT. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1990; 19:9-13. [PMID: 2166020 DOI: 10.1016/0360-3016(90)90127-6] [Citation(s) in RCA: 145] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
From 1970 through 1987, 77 patients with Stage I lung cancer were treated with definitive radiation therapy (RT) alone at the Fox Chase Cancer Center or the Hospital of The University of Pennsylvania. All patients had a pathologic diagnosis of non-small cell lung cancer and were not candidates for surgical resection because of premorbid medical problems or patient refusal. The median age was 72 years, although 10 patients were over 80. The histologic cell type was squamous in 44, adenocarcinoma in 15, large cell in 3, adenosquamous in 1, non-small cell in 11, and bronchioli-alveolar in 3. Tumor size was retrievable in 75 patients and 25 were less than or equal to 3 cm, 41 from 3-6 cm, and 9 greater than 6 cm. Diagnostic staging varied during the study period. Twelve patients, evaluated with a CT scan of the chest, including the liver, and a bone scan were classified as having "excellent" staging, 24 patients with conventional tomography, liver-spleen scan and a bone scan had "good" staging, and 41 patients were staged less rigorously. The RT was of megavoltage energy in all patients. The median dose was 60 Gy. The mediastinum was treated in all but eight patients who had poor pulmonary function. Survival was measured from the date of pathologic diagnosis. The actuarial 3-year survival rate of the entire group of patients is 17% with a median survival time of 20 months. Of the 61 deaths, 51 were due to disease and 10 were due to intercurrent disease without evidence of tumor recurrence. The actuarial 3-year disease-specific survival (DSS) was 22%. The 3-year disease-specific survival for patients with tumors less than 3 cm and from 3-6 cm was 30% and 17%, respectively. All nine patients with tumors greater than 6 cm were dead of disease. Local progression occurred in 33 patients, resulting in a 44%, 3-year actuarial freedom from local progression. The median time to local failure was 28 months and there were no local failures after 3 years in the 18 patients eligible for observation beyond this point. Of the patients with "excellent" staging, only 2 of 12 were dead of disease compared with 22 of 24 with "good" staging and 30 of 41 of the remainder. In this large group of Stage I non-small cell lung cancer, thorough pre-treatment staging and smaller tumor size are associated with a more favorable outcome.
Collapse
Affiliation(s)
- H M Sandler
- Department of Radiation Oncology, Fox Chase Cancer Center, University of Pennsylvania, Philadelphia
| | | | | |
Collapse
|